Work With Patients To Design Trials For Anti-Hypertensive Devices, FDA Advisors Suggest
Executive Summary
FDA is looking forward to reviewing PMAs from several anti-hypertension devices in the coming years – including technologies from Medtronic, ReCor Medical, ROX Medical, and Vascular Dynamics – so the agency convened its Circulatory System Devices Panel on Dec. 5 to get recommendation on pre-market clinical trial design, post-approval study design, indications and labeling for such devices.
You may also be interested in...
Cardiovascular Catch-Up: Medtronic And Edwards Make Headlines At TCT Conference
The first half of November was full of cardiovascular device news, led by clinical trial results from renal denervation and transcatheter aortic valve trials presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference.
SoniVie, ReCor Move Forward With Ultrasound Renal Denervation Technologies
The FDA granted its breakthrough designation to SoniVie’s TIVUS and ReCor's Paradise ultrasound renal denervation systems for treating hypertension.
Medtronic Hopes To Refine Renal Denervation Hypertension Therapy With New Trial
The 50-patient SPYRAL DYSTAL trial will evaluate the benefits of a new targeted renal denervation approach with the Symplicity Spyral renal denervation system in patients with uncontrolled hypertension.